ZBIO

Zenas BioPharma, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1953926Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$10.0M

Net Income FY2025

$(378.0M)

EPS (Basic, as reported)

$-8.44

Net Margin FY2025

-3777.4%

ROE FY2025

-156.0%

Total Equity

$242.0M

Shares Out

65M

Business description

Zenas BioPharma, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2023–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 50 → 10 -55.3% CAGR

Fiscal yearFY2023⚑FY2024⚑FY2025

Revenue50510

Research & development(60)(139)(168)

General & administrative(17)(30)(53)

Total operating expenses(87)(169)(393)

Operating income(37)(164)(383)

Interest expense——(7)

Interest & investment income—812

Other income (expense), net075

Pre-tax income(37)(157)(378)

Income tax expense000

Net income(37)(157)(378)

EPS — basic($24.25)($11.89)($8.44)

EPS — diluted($24.25)($11.89)($8.44)

Shares outstanding — basic (M)21345

Shares outstanding — diluted (M)21345

⚑ Weighted-average shares changed ×6.50 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×3.46 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.